Triple-negative breast cancer: Clinical features and patterns of recurrence

被引:3679
作者
Dent, Rebecca
Trudeau, Maureen
Pritchard, Kathleen I.
Hanna, Wedad M.
Kahn, Harriet K.
Sawka, Carol A.
Lickley, Lavina A.
Rawlinson, Ellen
Sun, Ping
Narod, Steven A.
机构
[1] Womens Coll Hosp, Womens Coll Res Inst, Toronto, ON M5G 1N8, Canada
[2] Univ Toronto, Toronto, ON, Canada
[3] Sunnybrook Hlth Sci Ctr, Dept Med Oncol, Toronto, ON, Canada
关键词
D O I
10.1158/1078-0432.CCR-06-3045
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: To compare the clinical features, natural history, and outcomes for women with "triple- negative" breast cancer with women with other types of breast cancer. Experimental Design: We studied a cohort of 1,601 patients with breast cancer, diagnosed between January 1987 and December 1997 at Women's College Hospital in Toronto. Triplenegative breast cancers were defined as those that were estrogen receptor negative, progesterone receptor negative, and HER2neu negative. The prognostic significance of triple-negative breast cancer was explored. Results: The median follow-up time of the 1,601 women was 8.1 years. One hundred and eighty of 1,601 patients (11.2%) had triple-negative breast cancer. Compared with other women with breast cancer, those with triple-negative breast cancer had an increased likelihood of distant recurrence (hazard ratio, 2.6; 95% confidence interval, 2.0-3.5; P < 0.0001) and death (hazard ratio, 3.2; 95% confidence interval, 2.3-4.5; P < 0.001) within 5 years of diagnosis but not thereafter. The pattern of recurrence was also qualitatively different; among the triple-negative group, the risk of distant recurrence peaked at similar to 3 years and declined rapidly thereafter. Among the "other" group, the recurrence risk seemed to be constant over the period of follow-up. Conclusions: Triple-negative breast cancers have a more aggressive clinical course than other forms of breast cancer, but the adverse effect is transient.
引用
收藏
页码:4429 / 4434
页数:6
相关论文
共 23 条
  • [1] High-throughput protein expression analysis using tissue microarray technology of a large well-characterised series identifies biologically distinct classes of breast cancer confirming recent cDNA expression analyses
    Abd El-Rehim, DM
    Ball, G
    Pinder, SE
    Rakha, E
    Paish, C
    Robertson, JFR
    Macmillan, D
    Blamey, RW
    Ellis, IO
    [J]. INTERNATIONAL JOURNAL OF CANCER, 2005, 116 (03) : 340 - 350
  • [2] Basal-like breast carcinomas: clinical outcome and response to chemotherapy
    Banerjee, S.
    Reis-Filho, J. S.
    Ashley, S.
    Steele, D.
    Ashworth, A.
    Lakhani, S. R.
    Smith, I. E.
    [J]. JOURNAL OF CLINICAL PATHOLOGY, 2006, 59 (07) : 729 - 735
  • [3] CAREY LA, 2004, BREAST CANC RES TREA, V80, P1023
  • [4] Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study
    Carey, Lisa A.
    Perou, Charles M.
    Livasy, Chad A.
    Dressler, Lynn G.
    Cowan, David
    Conway, Kathleen
    Karaca, Gamze
    Troester, Melissa A.
    Tse, Chiu Kit
    Edmiston, Sharon
    Deming, Sandra L.
    Geradts, Joseph
    Cheang, Maggie C. U.
    Nielsen, Torsten O.
    Moorman, Patricia G.
    Earp, H. Shelton
    Millikan, Robert C.
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2006, 295 (21): : 2492 - 2502
  • [5] A basal epithelial phenotype is more frequent in interval breast cancers compared with screen detected tumors
    Collett, K
    Stefansson, IM
    Eide, J
    Braaten, A
    Wang, H
    Eide, GE
    Thoresen, SO
    Foulkes, WD
    Akslen, LA
    [J]. CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2005, 14 (05) : 1108 - 1112
  • [6] Expression of luminal and basal cytokeratins in human breast carcinoma
    El-Rehim, DMA
    Pinder, SE
    Paish, CE
    Bell, J
    Blamey, R
    Robertson, JFR
    Nicholson, RI
    Ellis, IO
    [J]. JOURNAL OF PATHOLOGY, 2004, 203 (02) : 661 - 671
  • [7] The prognostic implication of the basal-like (cyclin Ehigh/p27low/p53+/glomeruloid-microvascular-proliferation+) phenotype of BRCA1-related breast cancer
    Foulkes, WD
    Brunet, JS
    Stefansson, IM
    Straume, O
    Chappuis, PO
    Bégin, LR
    Hamel, N
    Goffin, JR
    Wong, N
    Trudel, M
    Kapusta, L
    Porter, P
    Akslen, LA
    [J]. CANCER RESEARCH, 2004, 64 (03) : 830 - 835
  • [8] Disruption of the expected positive correlation between breast tumor size and lymph node status in BRCA1-related breast carcinoma
    Foulkes, WD
    Metcalfe, K
    Hanna, W
    Lynch, HT
    Ghadirian, P
    Tung, N
    Olopade, O
    Weber, B
    McLennan, J
    Olivotto, IA
    Sun, P
    Chappuis, PO
    Bégin, LR
    Brunet, JS
    Narod, SA
    [J]. CANCER, 2003, 98 (08) : 1569 - 1577
  • [9] Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer
    Foulkes, WD
    Stefansson, IM
    Chappuis, PO
    Bégin, LR
    Goffin, JR
    Wong, N
    Trudel, M
    Akslen, LA
    [J]. JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2003, 95 (19) : 1482 - 1485
  • [10] Molecular cytogenetic identification of subgroups of grade III invasive ductal breast carcinomas with different clinical outcomes
    Jones, C
    Ford, E
    Gillett, C
    Ryder, K
    Merrett, S
    Reis, JS
    Fulford, LG
    Hanby, A
    Lakhani, SR
    [J]. CLINICAL CANCER RESEARCH, 2004, 10 (18) : 5988 - 5997